Evidence map›Paper›PMID 39843919›Full record

SynthesisEuropean journal of human genetics : EJHG2025

Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice.

Jeanette Yuen, Siqin Zhou, Rebecca Caeser, Mallika Venkatramani, Diana Nur Bte Ishak, Shao-Tzu Li, Zewen Zhang, Jianbang Chiang, Sock Hoai Chan, Joanne Ngeow

Abstract readSystematic Review
In one paragraph

Synthesis in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Spring in EJHG.European journal of human genetics : EJHG · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jeanette YuenCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.ORCID 0000-0003-0046-3518
Siqin ZhouDivision of Clinical Trial & Epidemiological Sciences, National Cancer Centre, Singapore, Singapore.
Rebecca CaeserCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Mallika VenkatramaniCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Diana Nur Bte IshakCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Shao-Tzu LiCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Zewen ZhangCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Jianbang ChiangCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.ORCID 0000-0002-3109-2839
Sock Hoai ChanCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Joanne NgeowCancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore. joanne.ngeow@ntu.edu.sg.ORCID 0000-0003-1558-3627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The popularity of multi-gene testing has identified more families with two or more pathogenic variants (PV) in cancer predisposition genes, also known as 'MINAS' (multilocus inherited neoplasia alleles syndromes). They are at risk of suboptimal treatment and management as little on this topic is known. We conducted a systematic review of published MINAS cases within cancer predisposition genes to understand their association with more severe presentations. We analysed 413 MINAS carriers, which included 33 novel cases from the Cancer Genetics Service, National Cancer Centre Singapore. Statistical tests were conducted to assess association between carrier characteristics and the number PV identified. Results suggest that MINAS carriers have more malignancies (31.7% vs 21.5% vs 10.3% %; p < 0.001), a younger median age of first cancer diagnosis (40.0 vs. 44.0 vs. 49.0 years; p < 0.001) and an early onset of cancer (defined as <5% PV-associated cancer risk at age of diagnosis) (24.9% vs 7.7% vs 4.7%; p < 0.001) compared to monoallelic and non-carriers. We also studied the association of clinical characteristics by the dominant or recessive nature of PV harboured, where more dominant-dominant (D-D) carriers reported multiple malignancies (34.0%), compared to dominant-recessive (D-R) (23.9%) and recessive-recessive (R-R) carriers (20%;) (p = 0.051). Our findings suggest that MINAS carriers are prone to more and younger malignancies and the dominant or recessive nature of PV within double carriers can affect clinical presentation. We suggest a framework to guide management based on the dominant or recessive nature of PV within double PV carriers.

Indexed as

Genetic Predisposition to DiseaseNeoplasmsNeoplastic Syndromes, HereditaryAdultAllelesFemaleGenetic TestingHeterozygoteHumansMaleMiddle Aged

Identifiers

PMID39843919
PMCPMC11894078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.